Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.

Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.

A number of cell surface molecules with specificity to tumour cells have been identified and monoclonal antibodies (mAb) to some of these antigens have been used for targeting tumour cells in vivo. We have sought to link the powerful effector mechanisms of cytotoxic T-cells with the specificity of m...

Descripció completa

Dades bibliogràfiques
Autors principals:	Ogg, G, Dunbar, P, Cerundolo, V, McMichael, A, Lemoine, N, Savage, P
Format:	Journal article
Idioma:	English
Publicat:	2000

Ítems similars

Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.
per: Savage, P, et al.
Publicat: (2002)

Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent.
per: Whelan, J, et al.
Publicat: (1999)

A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex.
per: Xu, X, et al.
Publicat: (2001)

Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region.
per: Wooldridge, L, et al.
Publicat: (2007)

Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface.
per: Wooldridge, L, et al.
Publicat: (2003)

Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice.
per: Savage, P, et al.
Publicat: (2002)

Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma.
per: Dunbar, P, et al.
Publicat: (1999)

Oligomeric MHC molecules and their homologues: state of the art.
per: Dunbar, P, et al.
Publicat: (2002)

Dendritic cell/tumour fusions are more efficient at eliciting MHC class I-restricted Ag-specific CTL responses when compared to antigen-pulsed dendritic cells
per: Galea-Lauri, J, et al.
Publicat: (2001)

INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE
per: Moots, R, et al.
Publicat: (1993)

INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE
per: Moots, R, et al.
Publicat: (1993)

A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity.
per: Elvin, J, et al.
Publicat: (1993)

Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules.
per: Colonna, M, et al.
Publicat: (1998)

Functions of nonclassical MHC and non-MHC-encoded class I molecules.
per: Braud, V, et al.
Publicat: (1999)

Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer.
per: Spies, T, et al.
Publicat: (1992)

Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL.
per: Beal, A, et al.
Publicat: (2008)

Structures of an MHC class I molecule from B21 chickens illustrate promiscuous peptide binding.
per: Koch, M, et al.
Publicat: (2007)

Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination.
per: Savage, P, et al.
Publicat: (2007)

Re-evaluating the peptide repertoire of MHC-E
per: S. Brackenridge, et al.
Publicat: (2017-12-01)

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
per: Chen, J, et al.
Publicat: (2000)

Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers.
per: Wooldridge, L, et al.
Publicat: (2006)

In vivo enhancement of tumour-specific T cells via peptide–MHC-pseudotyped retroviral gene delivery
per: Kwong, H, et al.
Publicat: (2025)

Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms.
per: Stewart-Jones, G, et al.
Publicat: (2012)

Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms.
per: Stewart-Jones, G, et al.
Publicat: (2012)

Kinetics of the HBV-specific CTL response
per: Maini, M, et al.
Publicat: (1999)

Production and crystallization of MHC class I B allele single peptide complexes.
per: Reid, S, et al.
Publicat: (1996)

MHC CLASS-I EXPRESSION IN TRANSPLANTATION TOLERANCE AND PEPTIDE PRESENTATION TO CTL - A MUTANT-CELL THAT FAILS TO PRESENT INTERNALLY DERIVED H-2 RESTRICTED ANTIGENS BUT REMAINS SENSITIVE TO ALLO H-2 SPECIFIC RESPONSES
per: Ohlen, C, et al.
Publicat: (1989)

CTLs target Th cells that acquire bystander MHC class I-peptide complex from APCs.
per: Cox, J, et al.
Publicat: (2007)

Extensive alanine substitutions increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and do not abrogate peptide-specific CTL recognition.
per: Collins, E, et al.
Publicat: (1999)

Tumour lysis syndrome: modern aspects of the problem
per: N. V. Matinyan, et al.
Publicat: (2022-11-01)

Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway.
per: Noakes, K, et al.
Publicat: (1999)

Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
per: Maczek, C, et al.
Publicat: (2005)

Mutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors
per: Yang, Yue, et al.
Publicat: (2011)

Mutational escape in HIV-1 CTL epitopes leads to increased binding to inhibitory myelomonocytic MHC class I receptors.
per: Yue Yang, et al.
Publicat: (2010-12-01)

TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide.
per: Braud, V, et al.
Publicat: (1998)

Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
per: Stephanie J. Crowley, et al.
Publicat: (2020-02-01)

Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours
per: Chrissie E. B. Ong, et al.
Publicat: (2022-10-01)

Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition.
per: Matsui, M, et al.
Publicat: (1995)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
per: Smith, C, et al.
Publicat: (2005)

Assembly of MHC class I molecules analyzed in vitro.
per: Townsend, A, et al.
Publicat: (1990)